Menu

Recent Interviews

Jerre Foo, Corporate Development Executive, Silkroad Nickel

Jerre Foo
Corporate Development Executive | Silkroad Nickel
50 Armenian Street #03-04, 179938 Singapore (SGP)

enquiries@silkroadnickel.com

+65 6327 8971

Silkroad Nickel: 'The course is set for dynamic profit growth.'


Dr. Thomas Gutschlag, CEO, Deutsche Rohstoff AG

Dr. Thomas Gutschlag
CEO | Deutsche Rohstoff AG
Q7, 24, 68161 Mannheim (D)

info@rohstoff.de

+49 621 490 817 0

Interview Deutsche Rohstoff AG: "We can imagine additional investments in the field of electromobility."


Steve Cope, President, CEO and Director, Silver Viper

Steve Cope
President, CEO and Director | Silver Viper
1055 W Hastings St Suite 1130, V6E 2E9 Vancouver (CAN)

info@silverviperminerals.com

+1-604-687-8566

Interview with Silver Viper: Future price drivers and takeover fantasy


09. December 2020 | 11:00 CET

JinkoSolar, Scottie Resources, Palantir - Buying the future!

  • Investments
Photo credits: Scottie Resources

Comparing the figures of companies with their stock market valuation at the moment could make you dizzy. Particularly in the future topics of hydrogen, photovoltaics or data analysis, market capitalizations are five to six years ahead. What is important here is an innovative business model, growth and above all, a dominant market position.

time to read: 3 minutes by Stefan Feulner


 

Author

Stefan Feulner

The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
He is passionate about analyzing a wide variety of business models and investigating new trends.

About the author


The Golden Triangle

With gold mines, of course, the first-class location of the mines and the high degree of mineralization are added to this. Here the Canadian gold exploration Company Scottie Resources has hit the bull's eye. Scottie Resources' projects are located in prime locations in the so-called "Golden Triangle". The Golden Triangle in British Columbia is one of the most productive mineralization areas in the world and is world-renowned for its rich deposits. The Canadians own more than 25,000 hectares in total. The claims also include a 100% interest in the high grade, formerly producing Scottie Gold Mine and Bow Properties.

Sensational results in the "Blueberry Zone"

Yesterday, Scottie Resources' management reported superior assay results for the Blueberry Zone of the Bow property. Bow is located just 2 kilometers northeast of the Scottie Mine. Also, a new direction of mineralization has been identified that is hostile to the historic Blueberry vein target. The intersection of several high-grade intercepts along the strike (including 22.3 grams per tonne gold over 6.1 metres) defines an intense mineralized line running north-south. This new target remains open along the strike and at depth, with numerous high-grade grab samples defining a zone with a strike length above 800 metres.

Full program next year

Scottie Resources CEO Bradley Rourke commented enthusiastically on the results: "Fantastic drill results in an ideal location. This new Blueberry trend is a near-surface target, literally situated on a road. The grades and widths of these results get us extremely excited about the economic potential of the area. Bolstered by the high-grade grab samples from this year, drilling in 2021 will see us aggressively step out along this new trend to establish the full extent of this remarkably large and high-grade system."**

Prestige order drives price jump

Palantir Technologies, a US-based provider of software and services related to the analysis of large amounts of data, has once again secured a strong new partner in the public sector. A three-year contract with a total value of USD 44.4 million has been signed with none other than the FDA, the Food and Drug Administration. In return, Palantir will provide the US Food and Drug Administration with its data integration and analysis services. Approximately 50% of Palantir's clients are currently private customers, with the other half of the contracts coming increasingly from government and intelligence circles. For example, Palantir has been commissioned by the US government to develop a system that will be used to track the production and distribution of Corona vaccines.

Currently still irrevocable rating

After reaching an all-time high of USD 33.00 last week, there was a brief, painful 30% correction to USD 21.00. The rebound, however, already came with the FDA notification. The Palantir share is currently trading at USD 30.00 again. Looking more closely at the figures for the third quarter, the current market value of USD 50.48 billion does not seem justified. Overall, however, Palantir is an absolute acquisition machine. The growth story is on track. Although the Americans still have to prove their stock market valuation, which is far too high at the moment, they are the undisputed market leader in the future topics of data analysis and artificial intelligence.

Figures at last

Investors had had to wait a long time for the quarterly figures of the Chinese photovoltaic manufacturer JinkoSolar. JinkoSolar could not report a real bang, but rather relatively stable results. So the Chinese have thus been able to expand their business further. Deliveries in the third quarter of the 2020 financial year reached almost 5.12 megawatts (MW), an increase of 53.8 % on the same period of the previous year. In the same period of the 2020 fiscal year, Company sales rose by 17.2%year-on-year to a total of USD 1.29 billion, thus meeting the upper estimates of analysts.

Margins weak

The development of the operating margin was less pleasing. At 6.1%, it was significantly lower than in the same period of the previous year. In September 2019, it was still at 8.5%. The net result was a profit of a meager USD 1.0 million. Although management is aiming for a global market share of 15% by 2021, the share initially went for a dive, but yesterday it was able to revise its initial losses during the day. The support zone at USD 60.00 is significant and should be maintained. In the long term, the story is on track.


Author

Stefan Feulner

The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
He is passionate about analyzing a wide variety of business models and investigating new trends.

About the author



Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.


Related comments:

20. April 2021 | 09:45 CET | by Stefan Feulner

Varta, Sierra Growth, CureVac - Clear signals!

  • Investments

Sometimes, for various reasons, it takes longer before the positive developments of a Company are absorbed by the market and thus provide for price gains. It is currently similar to the precious metal gold, which is still in the consolidation phase. The facts such as national debt, inflation fears and the ultra-loose monetary policy of the central banks speak another clear language.

Read

20. April 2021 | 07:10 CET | by Carsten Mainitz

BioNTech, SunMirror, Steinhoff - Great News!

  • Investments

Shortly before the finish line, the going gets tough again. Many athletes and those who have to really "bite" in the last few meters before a deadline are probably familiar with this feeling. Everyday life in the Corona pandemic is also becoming more exhausting. Now, with BioNTech's announcement that it will double weekly vaccine dose deliveries to around 5.1 million units from the end of May, there may be a breakthrough in achieving herd immunity in Germany in the next few months. It is not only good news for the Company's shareholders but everyone. Below we present two other companies whose shareholders should be very pleased. Let us surprise you!

Read

15. April 2021 | 07:15 CET | by Stefan Feulner

Alibaba, The Place Holdings, CureVac - Great opportunities lie here!

  • Investments

The German vaccination disaster is going into the next round. After the AstraZeneca vaccine's back and forth and the question of whether only younger people, older people or no one should be vaccinated with the vaccine, the American vaccine manufacturer Johnson & Johnson is now experiencing delivery stoppages. The return to "normality" once again seems to be a long way off. Another question to ask yourself. What will future life in the new normal look like in the hard-pressed inner cities?

Read